It will, therefore, be of interest to study if the relative abundance of NKG2A+CD57− NK cells predicts susceptibility to EBV-LPD or EBV+ IM, or if these subsets can be expanded in vivo or ex vivo and used therapeutically. This evidence concerns the gene B3GAT1 and disseminated peritoneal leiomyomatosis.